alpha-thio-CTP

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: alpha-thio-CTP
• 英文别名: CTPαS；[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
• 化学式: C₉H₁₆N₃O₁₃P₃S
• 分子量: 499.226
• InChiKey: MBIHBEVUNFGMSS-NOUWQNLYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  283
• 氢给体数：
  7
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  N-acetyl-2',3'-di-O-acetylcytidine 在 吡啶 、 氨 、 tris(tetra-n-butylammonium) hydrogen pyrophosphate 、 sulfur 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 alpha-thio-CTP
  参考文献：
  名称：

  Synthesis of Nucleoside α-Thiotriphosphates via an Oxathiaphospholane Approach^†

  摘要：

  Nucleoside 5 '-O-(alpha-thiotriphosphates) were obtained in reactions of the appropriate nucleoside 5 '-O-(2-thio-1,3,2-oxathiaphospholanes) with pyrophosphate in the presence of DBU. The presented method allows also for preparation of alpha-seleno congeners and corresponding a-modified diphosphates.

  DOI：

  10.1021/ol050617r

文献信息

• Sensitization of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP1884569A1

  公开（公告）日：2008-02-06

  The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents ; said short nucleic acid molecules are double-stranded short interfering nucleic acid molecules comprising a sense and an antisense region, wherein the sense region comprises a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70 % identity, preferably at least 80 % identity, more preferably at least 90 % identity with said sequences, and the antisense region comprises a nucleotide sequence that is complementary to the sense region.

  本发明涉及癌细胞抗药性基因的鉴定、通过RNA干扰抑制这些基因表达的短核酸分子及其在癌症治疗中作为辅助剂的用途，以使癌细胞对常规抗癌剂敏感；所述短核酸分子是由有义区和反义区组成的双链短干扰核酸分子，其中有义区包括选自以下组成的组的核苷酸序列：SEQ ID NO: 15、11、13、14、30、31、38、46、64和70：序列 SEQ ID NO：15、11、13、14、30、31、38、46、64 和 70 以及与上述序列具有至少 70% 的同一性，优选至少 80% 的同一性，更优选至少 90% 的同一性的序列，而反义区包括与有义区互补的核苷酸序列。
• Reversible siRNA-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
  申请人：Commissariat à l'Energie Atomique

  公开号：EP2014769A1

  公开（公告）日：2009-01-14

  Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutated huntingtin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models

  分离的双链短干扰核酸分子，可抑制表达上述两种亨廷丁基因的非人类哺乳动物细胞中内源性野生型亨廷丁基因和外源性人类突变亨廷丁基因的表达，及其在亨廷顿症治疗和啮齿动物模型亨廷顿症研究中的应用
• Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
  申请人：UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)

  公开号：EP2336320A1

  公开（公告）日：2011-06-22

  The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents ; said short nucleic acid molecules are double-stranded short interfering nucleic acid molecules comprising a sense and an antisense region, wherein the sense region comprises a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70 % identity, preferably at least 80 % identity, more preferably at least 90 % identity with said sequences, and the antisense region comprises a nucleotide sequence that is complementary to the sense region.

  本发明涉及癌细胞抗药性基因的鉴定、通过RNA干扰抑制这些基因表达的短核酸分子及其在癌症治疗中作为辅助剂的用途，以使癌细胞对常规抗癌剂敏感；所述短核酸分子是由有义区和反义区组成的双链短干扰核酸分子，其中有义区包括选自以下组成的组的核苷酸序列：SEQ ID NO: 15、11、13、14、30、31、38、46、64和70：序列 SEQ ID NO：15、11、13、14、30、31、38、46、64 和 70 以及与上述序列具有至少 70% 的同一性，优选至少 80% 的同一性，更优选至少 90% 的同一性的序列，而反义区包括与有义区互补的核苷酸序列。
• Metabolically stabilized double stranded mRNA
  申请人：University of Iowa Research Foundation

  公开号：US11007213B2

  公开（公告）日：2021-05-18

  Double stranded mRNA (ds mRNA), e.g., produced in vitro, where one strand encodes a protein of interest and the other strand is hydrogen bonded to at least a portion of the coding region for the protein, as well as methods of making and using the ds mRNA, are provided.

  提供了双链 mRNA（ds mRNA），例如在体外产生的双链 mRNA（ds mRNA），其中一条链编码感兴趣的蛋白质，另一条链与蛋白质编码区的至少一部分氢键结合，还提供了制造和使用 ds mRNA 的方法。
• Isolation of target nucleic acids
  申请人：GENETICS RESEARCH, LLC

  公开号：US11142788B2

  公开（公告）日：2021-10-12

  The invention provides methods of isolating a target nucleic acid in a sample. A primer is hybridized to the target. A polymerase and modified nucleotide resistant to nuclease degradation are used to extend the primer to create a modified polynucleotide. The sample is exposed to a nuclease, thereby isolating the modified polynucleotide. Optionally, the target nucleic acid may be further protected by binding a protein in a sequence specific manner to one end of the target nucleic acid to create a protected target nucleic acid resistant to nuclease degradation. Thus, after exposing the sample to a nuclease, the modified polynucleotide and protected target nucleic acid are isolated.

  本发明提供了在样品中分离目标核酸的方法。引物与目标核酸杂交。使用聚合酶和耐核酸酶降解的修饰核苷酸扩展引物，形成修饰多核苷酸。将样本暴露于核酸酶，从而分离出修饰的多核苷酸。可以选择将蛋白质以序列特异的方式与目标核酸的一端结合，进一步保护目标核酸，以产生抗核酸酶降解的受保护目标核酸。这样，将样品暴露于核酸酶后，就能分离出修饰的多核苷酸和受保护的靶核酸。